Sl.

No

Scrip

Sector

Remarks

Biocon

Pharma

Long term / Multi bagger

Conside 1. India's largest listed biotechnology fir 2.Company manufactures biotechnolog 3.Conducting R&D programs for interna 4.Indian phrama market is estimated to 5.Delay in approving patent is a major c

Bilcare

Considerations 1. India's largest listed biotechnology firm 2.Company manufactures biotechnological prodcts serving healthcare 3.Conducting R&D programs for international & pharma majors 4.Indian phrama market is estimated to grow by 17% per annm 5.Delay in approving patent is a major concern

52 Week High Low

P/E

EPS

Scrip 1.Entegra 2.Pratibha Indutries 3.KEC international 4.Godavari power &ispat 5.Gujarat state petronet 6.Yes Bank 7.REC 8.NESCO 9.HDFC 10.Power Finance Coporation 11.Cairn 12.Exide industries 13.Gail 14.Hdfc Bank 15.Idea 16.JP associates 17.Lupin 18.Pantaloon retail 19.Bilcare 20.Hindustan oil explrtn 21.Orchid chemicals 22.Delta Corp 23.DCB 24.Selan Exploration 25.Biocon 26.Simran pharama 27.Wochkardt 28.Karuturi 29.Vinati Organics 30.Smartlink

Remarks multi-enrich mid term- enrich ** / mid term- enrich uljk/ mid term- enrich uljk / mid term- enrich ** / mid term- enrich W.B W.B W.B W.B Double in 3yrs Double in 3yrs Double in 3yrs Double in 3yrs Double in 3yrs Double in 3yrs R.J / Double in 3yrs R.J / Double in 3yrs R.J / Oil price is a concern R.J R.J R.J R.J ** / Long term Debt 4000 cr High risk / High return

CMP

B.Price

N.avg

*** mostly recomended

tata communication biocon ranbaxy 650 fortis

Serial.No 1 2 3 4 5 6 7 8 9 10 11 12 13

Month April May June July August September October November December January February March April

Description

Carry